Array Biopharma, Inc. (ARRY) Reports Q2 Loss of 17c/Share
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.07 --0%
EPS Growth %: -70.0%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -70.0%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.10 better than the analyst estimate of ($0.27).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Array Technologies (ARRY) PT Lowered to $6 at Baird
- Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
- AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
